Immuron Ltd
ASX:IMC
Immuron Ltd
Research & Development
Immuron Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immuron Ltd
ASX:IMC
|
Research & Development
-AU$3.6m
|
CAGR 3-Years
-76%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-2%
|
|
|
Opthea Ltd
ASX:OPT
|
Research & Development
-$126.8m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
-37%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$34.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$171.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$65m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
-36%
|
|
Immuron Ltd
Glance View
Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The firm operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. The firm's flagship products include Travelan & Protectyn. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn is an anti-LPS antibodies, which target and remove harmful bacteria and LPS toxins in the gut. The firm focused on clinical development of three drug candidates and several in early-stage preclinical development.
See Also
What is Immuron Ltd's Research & Development?
Research & Development
-3.6m
AUD
Based on the financial report for Jun 30, 2025, Immuron Ltd's Research & Development amounts to -3.6m AUD.
What is Immuron Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-2%
Over the last year, the Research & Development growth was 33%. The average annual Research & Development growth rates for Immuron Ltd have been -76% over the past three years , -25% over the past five years , and -2% over the past ten years .
